Business Context and Reporting Period
This Form 6-K filing by Park Ha Biological Technology Co., Ltd. covers the month of January 2025, specifically dated January 7, 2025. The report discloses corporate governance changes regarding the appointment of a new independent director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The primary material change disclosed is the appointment of Da Yang as an independent director, effective January 7, 2025. The Board determined that Mr. Yang qualifies as an independent director under Nasdaq Stock Market LLC rules. He has no family relationship with existing directors or officers and has not been involved in reportable transactions with the Company in the past two years.
Guidance, Outlook, and Management Commentary
There is no financial guidance, outlook, or management commentary regarding business operations in this filing. The document notes that Mr. Yang will receive the Company's standard compensation for independent directors pursuant to an agreement attached as Exhibit 10.1. No risks, contingencies, or unusual items are disclosed.
Investor Verification Checklist
- Verify the terms of the Independent Director Agreement (Exhibit 10.1) to confirm specific compensation details.
- Confirm Mr. Yang's independence status and lack of conflicts of interest as stated in the filing.
- Review Mr. Yang's professional background in sales and marketing to assess his fit for the board.